There are exciting developments in Alzheimer’s research in Hawaiʻi. In November 2025, Hawaiʻi Pacific Neuroscience announced the launch of a new clinical trial for the novel Alzheimer’s Trontinemab treatment engineered with Brainshuttle™ Technology. Early research results have shown low rates of bleeding in the brain or ARIA (Amyloid Related Imaging Abnormalities) and a faster clearing of Amyloid plaques in the brain. Hawaiʻi Pacific Neuroscience is currently accepting study participants in Hawaiʻi who are 50 years to 90 years old and experiencing early stage Alzheimer’s disease. Learn more at their website and watch Dr. Liow’s KHON2 TV News Interview.

For more information, check out the NIH Clinical Trial Information or contact the Hawaiʻi Pacific Neuroscience Memory Disorder Center & Alzheimer’s Research Unit and call (808) 564-6141 or email info@HawaiiNeuroscience.com

This is listed for informational purposes only. The government does not review or approve the safety and science of all studies listed on this website. Choosing to join a study is an important personal decision. Before you join a study, learn about the possible risks and benefits and discuss all options with your health care professional.